• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脂质体两性霉素B(安必素)在地方性流行发展中国家治疗内脏利什曼病的疗效和安全性。

Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.

作者信息

Berman J D, Badaro R, Thakur C P, Wasunna K M, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson A D

机构信息

Biology Department, Walter Reed Army Institute of Research, Washington, DC, USA.

出版信息

Bull World Health Organ. 1998;76(1):25-32.

PMID:9615494
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2305623/
Abstract

Reported are the results of a study to determine the efficacy and safety of liposomal amphotericin B (AmBisome) for treating visceral leishmaniasis (kala-azar) in several developing countries where the disease is endemic (Brazil, India, and Kenya). At each study site, sequential cohorts of 10 patients each were treated with AmBisome at a dose of 2 mg.kg-1.day-1 (2 MKD). The first cohort received regimen 1:2 MKD on days 1-6 and day 10 (total dose: 14 mg/kg). If the efficacy with this regimen was satisfactory, a second cohort received regimen 2:2 MKD on days 1-4 and 10 (total dose: 10 mg/kg); and a third cohort received regimen 3:2 MKD on days 1, 5, and 10 (total dose: 6 mg/kg). In India, regimens 1, 2, and 3 (which were studied concurrently) each cured 100% of 10 patients. In Kenya, regimen 1 cured all 10 patients, regimen 2 cured 90% of 10 patients, but regimen 3 cured only 20% of 5 patients. In Brazil, regimen 1 was only partially curative: 5 of 13 patients (62%). Therefore, 15 patients were administered regimen 4 (2 MKD for 10 consecutive days; total dose, 20 mg/kg) and 13 patients were cured (83%). These results suggest that for the treatment of kala-azar the following doses of AmBisome should be administered: in India and Kenya, 2 mg/kg on days 1-4 and day 10; and in Brazil, 2 mg/kg on days 1-10.

摘要

报告了一项研究的结果,该研究旨在确定脂质体两性霉素B(安必素)在几个该疾病流行的发展中国家(巴西、印度和肯尼亚)治疗内脏利什曼病(黑热病)的疗效和安全性。在每个研究地点,每组10名患者按顺序接受剂量为2mg·kg⁻¹·天⁻¹(2MKD)的安必素治疗。第一组接受方案1:在第1 - 6天和第10天给予2MKD(总剂量:14mg/kg)。如果该方案的疗效令人满意,第二组接受方案2:在第1 - 4天和第10天给予2MKD(总剂量:10mg/kg);第三组接受方案3:在第1、5和10天给予2MKD(总剂量:6mg/kg)。在印度,方案1、2和3(同时进行研究)分别治愈了每组10名患者中的100%。在肯尼亚,方案1治愈了所有10名患者,方案2治愈了10名患者中的90%,但方案3仅治愈了5名患者中的20%。在巴西,方案1仅部分治愈:13名患者中有5名(62%)。因此,15名患者接受了方案4(连续10天给予2MKD;总剂量,20mg/kg),13名患者治愈(83%)。这些结果表明,对于黑热病的治疗,应给予以下剂量的安必素:在印度和肯尼亚,在第1 - 4天和第10天给予2mg/kg;在巴西,在第1 - 10天给予2mg/kg。

相似文献

1
Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.脂质体两性霉素B(安必素)在地方性流行发展中国家治疗内脏利什曼病的疗效和安全性。
Bull World Health Organ. 1998;76(1):25-32.
2
Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.用于治疗黑热病(内脏利什曼病)的口服有效药物:聚焦于米替福新和硝喹。
J Assoc Physicians India. 2003 Jul;51:686-90.
3
Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.用于治疗印度内脏利什曼病的两性霉素B胶体分散体。
Clin Infect Dis. 2006 Mar 1;42(5):608-13. doi: 10.1086/500138. Epub 2006 Jan 20.
4
New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.印度内脏利什曼病的新治疗方法:单剂量脂质体两性霉素B继以短疗程口服米替福新。
Clin Infect Dis. 2008 Oct 15;47(8):1000-6. doi: 10.1086/591972.
5
Daily versus alternate-day regimen of amphotericin B in the treatment of kala-azar: a randomized comparison.两性霉素B治疗黑热病的每日给药方案与隔日给药方案:一项随机对照比较
Bull World Health Organ. 1994;72(6):931-6.
6
Injectable paromomycin for Visceral leishmaniasis in India.印度用于治疗内脏利什曼病的注射用巴龙霉素
N Engl J Med. 2007 Jun 21;356(25):2571-81. doi: 10.1056/NEJMoa066536.
7
Single-dose liposomal amphotericin B for visceral leishmaniasis in India.印度单剂量脂质体两性霉素 B 治疗内脏利什曼病。
N Engl J Med. 2010 Feb 11;362(6):504-12. doi: 10.1056/NEJMoa0903627.
8
A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience.脂质体两性霉素B治疗婴幼儿内脏利什曼病的6天疗程:意大利的经验
J Antimicrob Chemother. 2004 Jul;54(1):217-20. doi: 10.1093/jac/dkh279. Epub 2004 May 18.
9
Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis.高剂量预成型两性霉素B脂肪乳剂输注治疗印度内脏利什曼病的安全性和有效性。
Am J Trop Med Hyg. 2009 May;80(5):700-3.
10
Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions.两性霉素B治疗印度内脏利什曼病:每日输注15天与隔日输注的疗效对比
Clin Infect Dis. 2007 Sep 1;45(5):556-61. doi: 10.1086/520665. Epub 2007 Jul 23.

引用本文的文献

1
Genome alteration of Leishmania orientalis under Amphotericin B inhibiting conditions.在两性霉素B抑制条件下东方利什曼原虫的基因组改变
PLoS Negl Trop Dis. 2024 Dec 17;18(12):e0012716. doi: 10.1371/journal.pntd.0012716. eCollection 2024 Dec.
2
Visceral Leishmaniasis in a Twin Pregnancy: A Case Report and Review of the Literature.双胎妊娠合并内脏利什曼病:一例报告及文献复习
J Clin Med. 2024 Apr 20;13(8):2400. doi: 10.3390/jcm13082400.
3
Estimating the proportion of relapse following treatment of Visceral Leishmaniasis: meta-analysis using Infectious Diseases Data Observatory (IDDO) systematic review.内脏利什曼病治疗后复发比例的估计:使用传染病数据观测站(IDDO)系统评价的荟萃分析
Lancet Reg Health Southeast Asia. 2023 Dec 6;22:100317. doi: 10.1016/j.lansea.2023.100317. eCollection 2024 Mar.
4
The paradigm of intracellular parasite survival and drug resistance in leishmanial parasite through genome plasticity and epigenetics: Perception and future perspective.通过基因组可塑性和表观遗传学理解利什曼原虫寄生虫体内寄生虫生存和耐药性的范例:认知和未来展望。
Front Cell Infect Microbiol. 2023 Feb 6;13:1001973. doi: 10.3389/fcimb.2023.1001973. eCollection 2023.
5
Amphotericin B resistance in Leishmania mexicana: Alterations to sterol metabolism and oxidative stress response.墨西哥利什曼原虫的两性霉素 B 耐药性:固醇代谢和氧化应激反应的改变。
PLoS Negl Trop Dis. 2022 Sep 28;16(9):e0010779. doi: 10.1371/journal.pntd.0010779. eCollection 2022 Sep.
6
Persistence and Changing Distribution of Leishmaniases in Kenya Require a Paradigm Shift.肯尼亚利什曼病的持续存在及分布变化需要范式转变。
J Parasitol Res. 2021 Oct 18;2021:9989581. doi: 10.1155/2021/9989581. eCollection 2021.
7
Accelerating kala-azar elimination in India.加速印度消除黑热病进程。
Indian J Med Res. 2020 Dec;152(6):538-540. doi: 10.4103/ijmr.IJMR_841_19.
8
Leishmaniasis: where are we and where are we heading?利什曼病:我们在哪里,我们要往哪里去?
Parasitol Res. 2021 May;120(5):1541-1554. doi: 10.1007/s00436-021-07139-2. Epub 2021 Apr 7.
9
Bio-guided isolation of anti-leishmanial natural products from Diospyros gracilescens L. (Ebenaceae).从柿树(柿树科)中生物导向分离抗利什曼原虫天然产物。
BMC Complement Med Ther. 2021 Mar 31;21(1):106. doi: 10.1186/s12906-021-03279-1.
10
Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis.内脏利什曼病治疗后的严重不良事件:系统评价和荟萃分析。
PLoS Negl Trop Dis. 2021 Mar 29;15(3):e0009302. doi: 10.1371/journal.pntd.0009302. eCollection 2021 Mar.

本文引用的文献

1
Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome).脂质体两性霉素B(安必素)短程治疗内脏利什曼病
Clin Infect Dis. 1996 Jun;22(6):938-43. doi: 10.1093/clinids/22.6.938.
2
Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study.印度三种脂质体两性霉素B(安必素)治疗方案用于内脏利什曼病的比较:一项随机剂量探索性研究。
Trans R Soc Trop Med Hyg. 1996 May-Jun;90(3):319-22. doi: 10.1016/s0035-9203(96)90271-0.
3
Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome).HIV感染患者的内脏利什曼病:高剂量脂质体两性霉素B(安必素)治疗
J Infect. 1996 Mar;32(2):133-7. doi: 10.1016/s0163-4453(96)91343-2.
4
Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources.苏丹南部的流行性内脏利什曼病:战时条件下资源有限时对极度虚弱患者的治疗
Ann Intern Med. 1996 Apr 1;124(7):664-72. doi: 10.7326/0003-4819-124-7-199604010-00007.
5
Evaluation of amphotericin B as a first line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kala-azar.两性霉素B与葡萄糖酸锑钠相比作为一线药物治疗新发病例黑热病的评估。
Indian J Med Res. 1993 Jul;97:170-5.
6
Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial.脂质体两性霉素B(安必素)治疗地中海内脏利什曼病:一项多中心试验。
Q J Med. 1994 Feb;87(2):75-81.
7
Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosal leishmaniasis.葡萄糖酸锑钠(喷他脒)28天和40天疗程治疗黏膜利什曼病的疗效
Am J Trop Med Hyg. 1994 Jul;51(1):77-82. doi: 10.4269/ajtmh.1994.51.77.
8
Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar.两性霉素与葡萄糖酸锑钠在印度黑热病一线治疗中的对比
Lancet. 1994 Dec 10;344(8937):1599-600. doi: 10.1016/s0140-6736(94)90406-5.
9
Daily versus alternate-day regimen of amphotericin B in the treatment of kala-azar: a randomized comparison.两性霉素B治疗黑热病的每日给药方案与隔日给药方案:一项随机对照比较
Bull World Health Organ. 1994;72(6):931-6.
10
Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration.纠正血清电解质失衡可预防两性霉素B给药期间的心律失常。
Natl Med J India. 1995 Jan-Feb;8(1):13-4.